Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective

BACKGROUND: The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcomes Results (LEADER) clinical trial demonstrated that liraglutide added to standard-of-care (SoC) therapy for type 2 diabetes (T2D) with established cardiovascular disease (CVD) or elevated cardiovascular (C...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clinicoecon Outcomes Res
Main Authors: Shah, Dhvani, Risebrough, Nancy A, Perdrizet, Johnna, Iyer, Neeraj N, Gamble, Cory, Dang-Tan, Tam
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6241540/
https://ncbi.nlm.nih.gov/pubmed/30532570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S180067
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados